Abstract 22q11-deletion (DiGeorge/velocardiofacial) syndrome (22q11DS) is modeled by mutation of murine transcription factor Tbx1. As part of efforts to identify transcriptional targets of Tbx1, we analyzed the transcriptome of the pharyngeal region of Df1/+;Tbx1 +/À embryos at 9.5 days of embryonic development using two independent microarray platforms. In this model, embryos are null for Tbx1, with hemizygosity of genes in cis with Tbx1 on one chromosome providing a positive control for array sensitivity. Reduced mRNA levels of genes deleted from Df1 were detected on both platforms. Expression level filtering and statistical analysis identified several genes that were consistently differentially expressed between mutant and wild type embryos. Real-time quantitative PCR and in situ hybridization validated diminished expression of Pax9 and Gcm2, genes known to be required for normal thymus and parathyroid gland morphogenesis, whereas Pax1, Hoxa3, Eya1, and Foxn1, which are similarly required, were not down-regulated. Gbx2, a gene required for normal arch artery development, was down-regulated specifically in the pharyngeal endoderm and the posterior part of pharyngeal arch 1, and is a potential point of cross talk between the Tbx1 and Fgf8 controlled pathways. These experiments highlight which genes and pathways potentially affected by lack of Tbx1, and whose role may be explored further by testing for epistasis using mouse mutants. D
Introduction
Deletion 22q11.2 (22q11DS) is the most common microdeletion syndrome in man with an incidence of approximately 1:4000 live births (Scambler, 2003) . The major malformations include congenital heart defects such as truncus arteriosus (TA) and interrupted aortic arch type B (IAA-B), hypo/aplasia of the parathyroid gland, hypo/aplasia of the thymus gland, and craniofacial dysmorphism. Velopharyngeal insufficiency is also a common problem, resulting in the diagnosis of velo-cardio-facial syndrome (VCFS); DiGeorge sequence is another diagnosis commonly made in affected individuals (Scambler, 2003) . Genetic studies, predominantly in the mouse, have identified TBX1, a Tbox transcription factor, as the major gene haploinsufficient in the syndrome (Baldini, 2004; Epstein, 2001) . Additional genes may play a modifying role, or have a major role in development of some features such as the cognitive and behavioral problems reported in this condition (Paylor et al., 2001) . However, in order to understand the developmental basis of 22q11DS, most attention has been directed at understanding the contribution of Tbx1 to embryogenesis.
Tbx1 is expressed in the mesoderm of the first pharyngeal pouch and the pharyngeal endoderm (PE) from embryonic day (E)8.0 (Garg et al., 2001; . At E9.5, expression is seen throughout the PE and is strongest in the third pouch area. At E10.5 when the fourth pouch has formed, Tbx1 is most strongly expressed in the posterior regions of the PE. At E9.5, Tbx1 is expressed in the mesenchyme underlying the hindbrain, but is not expressed in the neural crest. Tbx1 is also expressed in the region of the anterior (secondary heart field). At E9.5, Tbx1 is expressed in the muscular wall of the outflow tract and later at E11.5 in the endothelial and subendothelial cells. By E11.5, pharyngeal expression is largely limited to the fourth pouch.
The first mouse model of 22q11DS was provided by an engineered deletion of mouse chromosome 16, Df1, which reduces 22 genes to hemizygosity (Lindsay et al., 1999) . Investigations have shown that the embryological phenotype of Tbx1 +/À mutants is indistinguishable from that of deletion mutants (Df1 or Lgdel), that the phenotype of Df1 mutants can be rescued by a transgene containing Tbx1, and that Df1/+;Tbx1 +/À transheterozygotes have embryonic phenotypes indistinguishable from Tbx1 À/À embryos Merscher et al., 2001; Vitelli et al., 2002a) . Tbx1 +/À and Df1/+ embryos have a fully penetrant hypoplasia of the fourth pharyngeal arch artery at E10.5 which may recover by birth, so that approximately 20% of heterozygotes have a congenital heart defect such as an IAA-B, a malformation typical of 22q11DS . Tbx1
À/À and Df1/+;Tbx1
mice have an unsegmented pharynx, with a hypoplastic 2nd and no evident 3rd and 4th pouches, resulting in aplasia of the thymus and parathyroid glands. The null mice also have a cleft palate, and ear defects. Late stage null embryos have a common arterial trunk (Jerome and Papaioannou, 2001 ). In one targeted mutant, Tbx1 coding sequences were replaced by a h-galactosidase gene, and staining of embryos revealed that Tbx1 lineage Tbx1 À/À cells are still present in null mutants Vitelli et al., 2002a) .
Tbx1 is regulated in part by Shh, which appears to act via Foxa2 and perhaps related Foxa and Foxc transcription factors (Yamagishi et al., 2003) . In the pharyngeal mesoderm, Foxa2 is selectively down-regulated in Tbx1 hypomorphic mutants suggesting a region-specific feedback loop (Hu et al., 2004) . Tbx1 hypomorphs also show an increased susceptibility of the cardiac outflow tract to the effects of reduced Tbx1 gene dosage (Hu et al., 2004; Xu et al., 2004) . Tbx1 itself can regulate Fgf8 and Fgf10 expression, and Fgf8 +/À ;Tbx1 +/À double heterozygotes have more severe cardiovascular defects than Tbx1 +/À mutants alone (Vitelli et al., 2002b) . Thus, while some of the targets of Tbx1 have been identified in these experiments, presumably many others remain to be identified.
In this paper, we report a microarray analysis of the transcriptome of Tbx1 À/À embryos at E9.5 which is aimed at identifying genes with quantitatively changed expression when compared to wild type. Differential expression of molecular markers may indicate a direct target of Tbx1, or an indirect target whose altered expression gives clues as to developmental defects in particular tissues or cell populations. Genes with a known or plausible role in the genesis of structures affected in Tbx1 À/À mice and 22q11DS patients were analyzed further, by real-time quantitative PCR (RTQPCR) to corroborate the array data, and in situ hybridization to assess qualitative alterations of expression, relative quantitative differences between expression zones, and how far these might be attributable to anatomical disruption in the null mutants as opposed to a change with potentially more biologically relevant effect. As Tbx1 is a transcriptional activator (Xu et al., 2004; Ataliotis et al., 2005) , we concentrated on down-regulated genes. We identified Pax9, Gcm2, and Gbx2 as quantitatively reduced in expression and suggest that these genes represent good candidates for Tbx1 target genes, or are expressed in Tbx1-expressing cell lineages absent or underrepresented in null mutant embryos.
Materials and methods

Mouse strains, breeding, and genotyping
The generation of Df1/+ and Tbx1 +/À mutant mice has been described (Lindsay et al., 1999 ). Mutants were maintained on a mixed C57Bl/6 background. Df1/+ and Tbx1 +/À mice were inter-crossed to generate transheterozygous mutants. Genotyping of embryos was carried out by PCR analysis of yolk sac or tail tip genomic DNA as described previously (Lindsay et al., 1999 ). Embryos were obtained from timed mated females and staged by somite counting.
RNA extraction, amplification, and hybridization of microarray probes
The pharyngeal region was dissected out from five E9.5 Df1/+;Tbx1 +/À and five somite stage-matched wild type mouse embryos; this region included the major Tbx1-expressing tissues as described above. The neural tube was dissected away to reduce the effects from dilution by non-Tbx1-expressing cells. The tissue was homogenized in 800 Al TRIzol (Invitrogen) and RNA extracted according to the manufacturer's protocol. After analysis on an Agilent Bioanalyzer, one wild type RNA preparation was rejected as marginally degraded. Each entire RNA sample was amplified using the MessageAmpi aRNA Kit (Ambion), according to the manufacturer's instructions. For generation of targets to be hybridized with MGU74Av2 GeneChip arrays (Affymetrix Inc., Santa Clara, California), a second round of amplification was then carried out using 2 Ag of first round aRNA to synthesize double-stranded cDNA, and incorporating biotin-11-CTP (Enzo Biochemicals) and biotin-16-UTP (Roche Molecular Biochemicals) during the subsequent transcription step. After both first and second rounds of transcription, samples were treated with DNAseI to remove contaminating DNA. For targets to be hybridized with CodeLink Bioarrays (Amersham Biosciences), double stranded cDNA was generated from first round aRNA as above, then biotinylated target cRNA was transcribed as per the CodeLink Expression Bioarray System protocol (avail-able on the website, http://www1.amershambiosciences. com). Biotinylated target aRNAs were hybridized to either MGU74Av2 GeneChipR arrays (Affymetrix) or CodeLink Mouse Uniset 1 Bioarrays (Amersham Biosciences) following standard procedures (http://www.affymetrix.com, and the Amersham Biosciences website, as above).
Data analysis (CodeLink Mouse Uniset 1 Bioarrays)
These arrays allow the analysis of 9991 genes, each represented by a single oligonucleotide. After imaging on an Axon scanner, the signal intensity at each probe was calculated. Intensity was defined as the sum of the pixel signals in the area of interest minus the scaled 2-pixel median background. The intensities were then mediannormalized by calculating the median of all spots except for the control probes and blanks and dividing each spot intensity by the median value. After median normalization, the negative control threshold was calculated using a set of pre-determined negative controls. The correlation coefficient was calculated for iterative pairwise comparisons of each wild type array and, separately, each experimental array as the Pearson product moment correlation coefficient.
Data analysis (Affymetrix GeneChip MGU74Av2 arrays)
The MGU74Av2 arrays enable the analysis of 12,488 transcripts including all sequences in the Mouse Unigene database (Build 74) and additional EST clusters, with each transcript being represented by 16 pairs of oligonucleotide probes (25mers). One of each pair of 25mers contains a single mis-match. The microarrays were scanned using a confocal argon -ion laser. The raw image data were analyzed using Microarray Analysis Suite version 5.0 software, with the data for each chip being normalized to a target intensity value of 100. The scaling factors used to normalize the target values for the 9 chips used were within 3-fold of each other (range 0.311 -0.724). The arrays used demonstrated control parameters for raw Q and background that were within recommended limits (raw Q < 4, background < 100) although the 3V/5V beta-actin and GAPDH ratios were higher than the recommended limit of 3. This was likely due to the amplification process leading to the generation of targets skewed to the 3Vend. Therefore, the 3V/ Middle probe set ratio (3V/M) was also calculated for GAPDH, as this was considered more likely to give a realistic indication of the reliability of the microarray data. The 3V/M ratio was <2 for all the chips.
Genespring analysis
Genespring software version 4.2.1 (Silicon Genetics, Inc., Redwood City, California) was used for the comparison of wild type and mutant arrays. Per chip normalization was carried out for both types of arrays, using the 50th percentile of all measurements (if above negative control threshold) as a positive control for each sample. Measurements for each gene were divided by this synthetic positive control. This was followed by per gene normalization, for which all wild type samples were normalized to 1, and all mutant samples were normalized to the wild type samples. The data from the MGU74Av2 arrays were then filtered to exclude genes with signals below the minimum control strength, and genes giving a detection P value of less than 0.1 in 5 out of 9 chips (the latter filter excludes genes which show a high degree of hybridization to the mis-match oligonucleotides on the arrays i.e. non-specific hybridization). For both types of arrays, the filtered normalized data were then analyzed to identify genes showing relative normalized expression of <0.8 or >1.2 on at least four out of five chips hybridized with mutant target. The resulting gene lists were statistically analyzed using the Wilcoxon-MannWhitney test, with a P value cut-off of 0.05, and applying the Benjamini and Hochberg False Discovery multiple testing correction. The data presented in tabular form in Results show the mean relative values for genes on the 5 mutant chips. Functional categories for genes were assigned using GO terms from the Gene Ontology Consortium (www.geneontology.org).
Quantitative real-time PCR
For validation of the microarray results, aRNA from pools of wild type and pools of Df1/+;Tbx1 +/À embryos was synthesized. 1 Ag of pooled wild type or mutant aRNA was reverse transcribed using Superscript II (Invitrogen) according to the manufacturer's instructions, in a total volume of 20 Al. The resulting cDNA was diluted 1:5 (1:250 when measuring GAPDH). RTQPCR was performed using SYBRGreen for the detection of fluorescence during amplification. Each amplification reaction contained 10 Al of Quantitect SYBR Green PCR master mix (Qiagen), 0.2 Ag each of forward and reverse primers, and 1 Al diluted cDNA in a total volume of 20 Al. All primers were designed with annealing temperatures of 57-59-C (sequences available on request). PCR conditions were 95-C for 15 min, followed by 40 cycles of 95-C for 30 s, 57-59-C for 30 s, and 72-C for 30 s. For genes except Fhl2, Txnrd2, Gbx2, and HoxA3, reactions were performed in duplicate or quadruplicate in a Smart CyclerR System (Cepheid) and the data analyzed using the Smart Cycler software. The other genes were amplified on an ABI7900. At least 3 separate analyses were carried out for each gene. Melt curve analysis was performed after each run to check for the presence of non-specific PCR products and primer dimers. Ct values were related to copy numbers using standard curves (as described previously; Roberts et al., 2005) . For each gene examined, a specific PCR fragment was synthesized that was extended at least 20-30 bp upstream and downstream of the amplicon generated by the primers used for the RTQPCR. Normalization was performed using GAPDH as an internal control as described (Roberts et al., 2005) .
Whole-mount in situ hybridization
Digoxygenin-labeled RNA probes were prepared by standard methods. Probes were kindly provided by Alexandra Joyner (Gbx2), C. Clare Blackburn (Gcm2, with permission from David J. Anderson), Rudi Balling (Pax9), Peter Gruss (Pax1), Ursula Drager (Raldh2), Pin Xu (Eya1) and Brigid Hogan (FoxA2). HoxA3 riboprobe was synthesized using IMAGE clone 6476230. In situ hybridization was performed according to previously published methods (Wilkinson, 1992) . At least four somite staged wild type and mutant embryos were analyzed with each probe. Following the enzymatic color reaction, embryos were dehydrated through a graded ethanol series, embedded in paraffin wax and sectioned at 10 -12 Am. Sections were counter-stained with eosin.
Promoter analysis
Upstream mouse and human genomic sequences for Gbx2, Pax9, Gcm2, Foxg1, Sox3, and Six2 were obtained from the UCSC Genome Bioinformatics Site (http:// genome.cse.ucsc.edu/). Sequences were aligned using mVISTA, a set of programs for comparing DNA sequences from two or more species (Frazer et al., 2004; Mayor et al., 2000) , available at http://genome.lbl.gov/vista/index.shtml.
Results
Microarray analysis of wild type and Df1/+;Tbx1 +/À embryos; down-regulation of Df1 genes Expression profiles of somite-stage matched Df1/+; Tbx1 +/À and wild type embryos were determined by microarray analysis. Microarray targets were synthesized from RNA extracted from the major Tbx1-expressing tissues, namely pharyngeal arches and neighboring tissues, including mesenchyme underlying the hindbrain. Targets corresponding to individual wild type or mutant embryos were hybridized with both CodeLink Mouse Uniset 1 Bioarrays (Amersham Biosciences) and Affymetrix MGU74a GeneChip arrays. For the CodeLink arrays, correlation coefficients of 0.99 for each pair-wise comparison of the wild type chips, and 0.98 (0.97 -0.99) for pair-wise comparisons of the mutant chips showed that overall the noise and variability of the system were low. 7583 genes were above threshold detection levels on the Codelink arrays and 6696 on the Affymetrix arrays. GeneSpring software was used to analyze the microarray data, with gene expression in the wild type samples being used as a baseline for normalization.
Df1/+;Tbx1 +/À transheterozygous rather than Tbx1 À/À embryos were used so that the haploid genes from the Df1 deleted region would serve as internal controls to test the sensitivity of the microarray system and alert us to noise introduced by the RNA amplification process. Of the 14 probes representing 13 genes from the Df1 deleted region on the CodeLink Bioarrays, 11 showed reduced expression on arrays hybridized with Df1/+;Tbx1 +/À target (Table 1) , with a mean level of down-regulation of 0.56-fold, although one gene (Claudin 5) did not pass the filtering and statistical analyses applied to the data as a whole (see below). Txnrd2 was represented by two independent probes, both of which showed significantly reduced expression. Three transcripts (Tbx1, ES2, and Cdcrel1) were expressed below the threshold detection level. Therefore, the CodeLink microarray platform was sensitive enough to detect significantly decreased expression of 9 of 13 haploid genes in the mutant embryos. Tbx1 had poor probe design as discussed below. Furthermore, the expected ratios of gene expression in the mutant and wild type embryos appeared to have been conserved throughout the RNA amplification process. If the three genes not detected as expressed above threshold at E9.5 are excluded from analysis, then 9 of 10 Df1 genes were detected as significantly down-regulated by our Codelink analysis.
A similar pattern of down-regulated Df1 gene expression was observed on the Affymetrix MGU74Av2 arrays, including down-regulation of further genes not represented on the CodeLink arrays, although the data were more variable. 11 of 16 probes were expressed above threshold detection levels and this equated to 10 deleted Df1 genes out of a possible 13 that were represented on the arrays once double probe sets had been accounted for. Six of these 10 showed statistically significant down-regulation. Therefore, Table 1 Df1 genes analyzed by microarray
Affymetrix and CodeLink columns show relative expression on microarray chips hybridized with Df1/+;Tbx1 +/À target (averaged across 5 chips). N stands for not present on chip. Filtered (+ or À) indicates whether or not the probe passed quantitative and statistical filtering (see Materials and methods). L stands for low signal strength (below detection threshold) and * indicates poor array probe quality. the Codelink arrays appeared to offer greater sensitivity and accuracy than Affymetrix MGU74Av2 arrays.
Gene expression changes in the mutants
Genespring was used to identify non-Df1 genes showing altered expression in the mutants. For the purposes of this experiment, and in order not to exclude small yet significant changes in gene expression, down-regulated genes were defined as those showing normalized expression of 0.8 or less on four out of five Codelink chips hybridized with mutant target. Up-regulated genes were those with normalized expression of 1.2 or more on four out of five mutant chips (statistical analyses applied to the resultant gene lists are described in Materials and methods and were conducted using information from all arrays). A total of 105 genes in addition to the Df1 deleted genes showed statistically significant downregulated expression on the CodeLink arrays, while 43 genes were up-regulated. The same analyses applied to the Affymetrix data yielded 215 down-regulated genes, and 216 upregulated genes. 25% of the genes selected on Codelink passed filtering on the Affymetrix analysis. The Codelink data are summarized in Tables 2 and 3 , with selected genes identified in the Affymetrix comparison included if represented on both arrays, or if they were considered plausible biological candidates. We concentrated on the Codelink data because of the improved detection of Df1-deleted genes as compared to Affymetrix arrays, and the smaller list size of differentially expressed genes which may have reflected greater specificity. The differentially expressed genes included several transcription factors, proteins involved in the synthesis and metabolism of retinoic acid, structural proteins, cell adhesion molecules, and cell signaling factors as well as several unknown genes/ESTs.
Real-time quantitative RT-PCR analysis of selected target genes
We carried out real-time quantitative reverse transcription-PCR analysis (RTQPCR) on selected genes in order to confirm the microarray results. The majority of changes in gene expression seen on the arrays were small, meaning that a sensitive method of validation was required. To test realtime PCR as a potential validation method, we first used it to analyze expression of three of the haploid Df1 genes: Comt, Cdc45l, and Txnrd2. In agreement with the microarray results, these genes showed 2-fold or greater downregulation of expression by RTQPCR (Table 4) . Further genes were then selected for PCR validation because of their biological relevance and/or because differential expression was seen on both CodeLink and Affymetrix arrays. A number of genes that were similarly down-regulated on both Affymetrix and CodeLink arrays also showed reduced expression by RTQPCR in Df1/+;Tbx1 +/À samples (Table  4) . Pax9, Foxg1, and Follistatin showed decreases in expression that correlated well with the microarray results; CL column shows relative expression on CodeLink Uniset Mouse 1 microarray chips hybridized with Df1/+;Tbx1 +/À target (averaged across 5 chips). All the genes listed passed the quantitative and statistical filtering parameters for down-regulation as described in Materials and methods. Genes selected from Affymetrix were additional genes considered to be of biological interest that were down-regulated on the Affymetrix MGU74Av2 microarrays but not represented on the CodeLink chips. In the Affy column, * indicates that genes were also down-regulated on the Affymetrix MGU74Av2microarrays, N means not present on the Affymetrix MGU74Av2 microarrays.
however, others showed slightly greater (Cyp26A1 and Pdlim3) or smaller (Six2, Dab2) changes in expression. We were also interested in two genes that were present only on the Affymetrix chips, Gcm2 and Sox3. Gcm2 is required early in the developing parathyroid (Gordon et al., 2001) , an organ which is hypoplastic in Tbx1 null mice (Jerome and Papaioannou, 2001 ). Interestingly, we observed a far greater reduction of Gcm2 expression in Tbx1 nulls by RTQPCR than by microarrays (5-fold as compared to 1.6-fold). Sox3 was marginally reduced. We looked at three genes, Et-1, Aldh1a1, and Fhl2, where there was disagreement between the two types of microarray. Although the expression of Et-1 and Aldh1a1 was reduced somewhat in the mutants on both types of microarray, the reduction on the CodeLink arrays was not sufficient to pass through the data filtering step. For Fhl2, only the CodeLink arrays showed a decrease. In each case, RTQPCR showed a decrease in expression, albeit a 20% reduction for Fhl2.
Finally, we looked at genes that showed the largest increases in expression on the CodeLink arrays, Raldh2 and HoxA5 (increased by 11.5-and 5.5-fold, respectively). Both genes were also increased on the Affymetrix arrays, though to a lesser extent. RTQPCR confirmed that both of these genes were up-regulated in the mutant RNAs. Again, the PCR results correlated better with the CodeLink results, with fold increases of 18.7 and 3.5 for Raldh2 and HoxA5, respectively. Therefore, overall (with the exception of Sox3) data obtained by RTQPCR confirmed the expression changes seen on the microarrays.
In situ hybridizations
In situ hybridization served as an independent method of validating the microarray results, enabling assessment of qualitative changes in gene expression in Tbx1 null embryos, as well as comparing the relative intensity of staining as a measure of expression level. A single mix of probe and hybridization solution was used to examine wild type and mutant embryos in adjacent wells of a six well dish in order to keep experimental conditions as closely similar as possible between the two groups of embryos. Analysis of Tbx1 expression as determined by h-galactosidase activity confirms previous data that Tbx1 lineage cells are still present in Tbx1 À/À embryos (Figs.  1A,B) . Expression is observed in the PE, the ectoderm over the branchial arches, and the mesodermal cores of the arches. However, in Tbx1 À/À embryos, a single zone of h-galactosidase expression of uniform intensity is seen in the unsegmented PE of mutants, in contradistinction to the relative abundance of transcripts in the posterior of the second and third pouches at this stage. We selected Pax9, Gcm2, and Gbx2 for in situ analysis because of their expression in the PE, which overlaps with that of Tbx1, and their functional role (see below). At E9.5, Pax9 expression domains include the pharyngeal pouches and sclerotome (Neubuser et al., 1995; Peters et al., 1998) . In agreement with the real-time PCR and microarray results, whole-mounts of Tbx1 À/À embryos at this stage showed decreased Pax9 transcripts in the pharyngeal region (Fig. 1B) . Sclerotomal expression was unaltered. As the caudal pouches are not formed in the Tbx1 À/À embryos, it was necessary to section the embryos in order to examine Pax9 expression in the endoderm. Coronal sections showed that expression in the endodermal cell layer in the Tbx1 nulls was much reduced compared to wild type embryos, particularly when comparing the caudal region of the unsegmented mutant endoderm to pouch III of the wild type (Fig. 1C) . In contrast, Pax1 expression was found to be robust in Tbx1 À/À embryos with no evidence of qualitative or quantitative changes in expression in the PE (Fig. 1D) . Similarly, focussing on the PE, the expression of Foxa2 is qualitatively and quantitatively maintained in this tissue, even in the more caudal region of the pharynx (and foregut), where Pax9 expression is most reduced (Fig. 1E) . Hoxa3 was similarly expressed in the PE, but also in crest derived mesenchyme; expression in both the PE and crest derived mesenchyme was maintained in Tbx1 À/À embryos (Fig. 1F) , and was quantitatively unaffected as determined by RTQPCR (Table 4) .
In order to examine whether Pax9 expression is altered prior to the appearance of the pharyngeal pouches, we conducted in situ hybridizations of E8.5 embryos. At this stage, embryos cannot be correctly genotyped on the basis of phenotype i.e. there is no obvious tissue loss in Tbx1 À/À embryos. Pax9 expression was consistently reduced in the pharyngeal region of E8.5 embryos, although the extent of expression was broadly equivalent (Figs. 1G,H) .
Gcm2 has a very restricted pattern of expression in the pharyngeal pouches (Gordon et al., 2001 ). At E9.5, there is diffuse expression in the 2nd and 3rd pharyngeal pouches, which becomes confined to the 3rd pouch by E10.5. As expression of Gcm2 is more distinct at E10.5, we compared expression in the Tbx1 wild type and mutant embryos at this stage. Gcm2 expression appeared to be completely absent in the Tbx1 null embryos by whole-mount (Fig. 1I) at this stage. Serial sectioning confirmed the absence of Gcm2 expression in the unsegmented endodermal tissue (Fig. 1J) . Thus, although the microarray results implied downregulation of Gcm2 in the absence of Tbx1, in situ analysis showed a complete loss of expression in the null embryos, more consistent with the RTQPCR data.
In situ hybridizations of E10.5 embryos showed decreased expression of Gbx2 in the PE in all mutant embryos analyzed, and a zone of expression in the posterior portion of the first arch was absent in approximately half of all mutants (Figs. 1K,Li vs. Liii). In other embryos, a generalized reduction in expression (Fig. 1Lii vs. Liv) was observed. At E9.5, Gbx2 expression was not as strong as at E10.5, but a reduction of expression in the PE and first branchial arch can still be seen (Fig. 1M ). Sections at this stage indicated (Fig. 1N) . For Raldh2, a retinaldehyde dehydrogenase responsible for early embryonic retinoic acid synthesis, the microarray and real-time PCR results suggested a large increase in mRNA levels in the mutant embryos. However, by in situ analysis of E9.5 wild type and Tbx1 mutant mouse embryos, this did not appear to be the case. At E9.5, Raldh2 is expressed in the splanchnic mesoderm with a boundary caudal to the foregut pocket, in the mesenchyme surrounding the cervical spinal cord and spinal ganglia, and in the somites, decreasing with differentiation (Niederreither et al., 1997 (Niederreither et al., , 2003 . The level of transcripts in these regions did not appear to be increased in the mutants; however, we observed an apparent anterior shift in the splanchnic mesodermal expression which is likely to account for the microarray results, these expressing regions being brought into the dissected area ( Fig. 2A) . This is confirmed by examination of sagital sections, where in null embryos the distance from the anterior border of Raldh2-expressing cells is much closer to landmarks such as the first branchial arch than in wild types (Fig. 2B) . Null embryos appeared to have increased Raldh2 expression in a region just anterior to the first arch in an area where expression could only just be discerned in wild type embryos ( Fig. 2A) . Sections indicated that these transcripts are in mesenchymal cells between the forebrain and the dorsal aorta (Fig. 2C) .
Analysis of upstream genomic regions for Tbx1 binding sites
We examined the promoter regions of a number of the validated target genes for potential Tbx1 binding sites. The mVISTA program was used to align 5kb of upstream human and mouse genomic sequences from Gbx2, Pax9, Sox3, Foxg1, and Six2; it was not possible to align mouse and human sequence upstream of Gcm2 due to the mouse sequence still being in unordered pieces. As Tbx1 has been shown to activate the Fgf10 promoter through a conserved T-Box binding element (TBE) with the sequence GTGTGA (Agarwal et al., 2003; Xu et al., 2004) , conserved regions of the above promoters were examined for identical or highly similar elements. Three conserved TBEs were identified upstream of Gbx2 (Fig. 3A) ; site a was located slightly upstream of the first conserved region, however was fully conserved between mouse and human. Two potential TBEs were also found to be conserved upstream of Pax9 (Fig.  3B) . In addition, a single conserved site was identified in both the Foxg1 and Sox3 promoters; however, no TBEs were found upstream of Six2 (data not shown).
Discussion
22q11DS causes a wide range of congenital abnormalities, and in humans is predominantly associated with hemizygosity for approximately 3Mb of DNA, encoding at least 35 genes. Chromosome engineering, transgenic complementation, and gene targeting experiments revealed that haploinsufficiency of the transcription factor Tbx1 was sufficient to produce a partial phenocopy of the syndrome. Tbx1 À/À embryos have a more severe spectrum of defects, such as persistent truncus arteriosus, absence of the thymus and parathyroid glands, and craniofacial dysmorphism, all observed in 22q11DS patients. Tbx1 acts a transcriptional activator, and thus identification of downstream targets of Tbx1 will be vital in elucidating the developmental pathways affected in 22q11DS. The identification of transcription factor targets represents a considerable challenge with several techniques having been developed, but no single methodology representing the approach of choice.
Here, we have used an expression microarray analysis to identify alterations in the transcriptome of Df1/+;Tbx1 +/À transheterozygous mice. This approach has several advanNotes to Table 3: CL column shows relative expression on CodeLink Uniset Mouse 1 microarray chips hybridized with Df1/+;Tbx1 +/À target (averaged across 5 chips). All the genes listed passed the quantitative and statistical filtering parameters for up-regulation as described in Materials and methods. In the Affy column, * indicates that genes were also up-regulated on the Affymetrix MGU74Av2 microarrays, N means not present on the Affymetrix MGU74Av2 microarrays. Values indicate expression levels in pooled Df1/+;Tbx1 +/À RNA samples from at least four embryo dissections relative to wild type as determined by real-time quantitative PCR carried out on the Cepheid SmartCycler or a ABI 7000 (corrected for GADPH expression, mean of at least three separate experiments, Tstandard deviation). tages and limitations. As Df1/+;Tbx1 +/À transheterozygotes have the same embryonic phenotype as Tbx1 À/À embryos, they provide a good model for absence of Tbx1 expression. 21 genes mapping to the Df1 interval in cis with Tbx1 are reduced to hemizygosity and we have previously shown that none of these genes are subject to dosage compensation (i.e. none of the remaining alleles are regulated back to dizygous expression levels) (Prescott et al., 2005) . Thus, these genes can be used as internal controls of array and hybridization quality. The cDNA microarray technology allows a screen of several thousand potential targets and, if present on the arrays with above detection threshold expression levels, the expression of candidate targets can be interrogated. Dissection of carefully staged embryos to derive mRNA from the Tbx1-expressing region should have increased the signal: noise ratio. On the other hand, at E9.5, the hypo/aplasia of the caudal branchial arches inevitably means that some detected changes will be due to anatomical disruption affecting cell types not expressing Tbx1. The h-galactosidase knock in marker indicates that Tbx1-lineage cells are clearly present in null embryos at E9.5. Thus, genes detected as differentiallyregulated may be downstream of Tbx1 in a developmental pathway, or they may be markers for a subset of cells which require Tbx1 for their proliferation or survival, or they may be expressed in cell types affected secondarily by the mutation. To some extent, these issues can be addressed by in situ expression analysis of the differentially expressed gene in mutant and control embryos, and by analysis of other genes known to be expressed in pharyngeal mesendoderm and branchial arch mesenchyme. Conducting in situ hybridizations on Tbx1 À/À opposed to Df1/+;Tbx1 +/À embryos will also detect any unsuspected effect the Df1 deletion might have had on the microarray data. The microarray and in situ hybridization data presented here identify both quantitative and qualitative changes in gene expression in Df1/+;Tbx1 +/À and Tbx1 À/À embryos, but independent methods will be required to identify primary transcriptional targets of Tbx1 from within the group of differentially expressed genes highlighted in this study.
We found that linear-amplified target derived from dissections of single embryos could consistently distinguish between transheterozygote and wild type embryos on the basis of Df1 gene expression level. This was most evident for the Codelink arrays, partly because of the number of Df1 genes represented on the array, and partly because of the choice of probe sequence (some Affymetrix sequences did not correctly represent the gene in question). Tbx1 itself was not present on the Affymetrix array, and was below detection threshold on the Codelink array. This is probably because the probe chosen represents the less abundant ''a'' check splice variant (Chieffo et al., 1997) which has a distinct 3V UTR, rather than the predominant ''c'' variant (Gong et al., 2001) .
Genes expressed in the pharyngeal endoderm/involved in thymic and parathyroid morphogenesis Pax9 was reduced in expression on the Codelink arrays, and expressed at 53% wild type levels by RTQPCR. The reduced expression in the PE is unlikely to be due to simple consequence of defective thymus and parathyroid precursor development as other genes critical for development of these structures, which are also expressed in PE and the pharyngeal arches, are not down-regulated. These genes include Eya1 (no change on either array set, RTQPCR, or in situ (data not shown)), Foxa1/2 (see below), Hoxa3 (no change on either array set, by RTQPCR or by in situ), and Pax1 (no change Codelink, slight increase on Affymetrix, no change on in situ). Eya1 is required for the morphogenesis of mammalian ear, kidney, thymus, parathyroid, and thyroid (Xu et al., 2002) . Hoxa3 À/À mice fail to develop a thymus or parathyroid gland and have heart defects (Manley and Capecchi, 1995) . Pax1 mutants fail to develop parathyroid glands and have a small thymus (Wilm et al., 1998) ; Hoxa3 and Pax1 have been shown to interact epistatically in this pathway .
Previous analysis of Pax9 in E9.5 Tbx1 À/À embryos demonstrated the presence of Pax9 expression in PE (Hu et al., 2004) , and this is confirmed by our in situ hybridizations. However, Pax9 expression appears reduced in Tbx1 null vs. wild type PE, particularly in more caudal regions. At this stage, we detected no change in expression of Pax1 or Foxa2 within the PE, consistent with the microarray analysis. Furthermore, Pax9 was consistently reduced at E8.5 (11-13 somites) prior to the formation of the caudal pharyngeal pouches and any gross anatomical abnormalities in Tbx1 À/À embryos. Pax9 À/À mice die shortly after birth, most likely as a consequence of a cleft secondary palate. They lack a thymus, parathyroid glands, and ultimobranchial bodies, organs which are derived from the pharyngeal pouches . PECAM staining of Pax9 À/À mutant embryos (E10.5) has revealed aortic arch patterning defects such as persisting first aortic artery, although this phenotype is apparently not completely penetrant (Heiko Peters, personal communication) . Thus, reduction of Pax9 expression levels in the PE may contribute to the Tbx1 À/À phenotype, but the Hoxa3/Pax1-regulated pathway is unlikely to be affected.
Gcm2 was down-regulated in the Affymetrix arrays (not present on Codelink), and expressed at 20% wt levels by RTQPCR. The underestimation of relative expression changes in microarray experiments vs. quantitative PCR has been commented upon previously (Yoshida et al., 2004) and is likely to be secondary to increased background noise and limited sensitivity. Gcm2 is expressed specifically in the developing second and third pharyngeal pouches at E9.5, and is further confined to a small domain of the third pouch endoderm by E10.5, and is a definitive marker of the parathyroid gland (Gordon et al., 2001 ). Whole-mount in situ hybridization of Tbx1 À/À embryos failed to detect Gcm2 expression in the PE at E10.5, and no expression was seen on serial sections through the pharyngeal region. At this stage, Gcm2 is expressed in the common thymic and parathyroid primordia. These results are similar to those seen in Eya1 and Hoxa3 null mice, where Gcm2 is absent at E10.5 , and Pax1 and Pax9 mutants where it is reduced (Xu et al., 2002) . It is possible that the reduction of Gcm2 expression observed is because Tbx1 is required for the development of progenitors of Gcm2-expressing cells, or that Tbx1 is required for Gcm2 expression in PE derivatives.
Foxa2 (and Foxc2) has been proposed to act upstream of Tbx1, and Foxa2 to be regulated by Tbx1 in the pharyngeal mesoderm (Hu et al., 2004) . Foxa1/2 expression was unchanged on Codelink arrays, and Foxc2 was at 95% levels. Presumably, the array analysis was insufficiently sensitive to detect the reduced mesodermal expression. Foxh1, required for development of the anterior heart field and its derivatives the right ventricle and outflow tract (von Both et al., 2004) , was detected at below threshold levels on the arrays. Mef2c, a Foxh1 target in the heart, was expressed at wild type levels on both arrays (von Both et al., 2004) . Foxg1 expression was reduced to approximately 65% wild type levels in both arrays and by RTQPCR. Foxg1 interferes with transforming growth factor beta signaling by associating with Smad partners, and is expressed in the PE as well as other developing head structures (Dou et al., 2000; Hebert and McConnell, 2000) . Null mutants die at birth and have defects of the eye and telencephalon (Xuan et al., 1995) ; the cause of death is unknown.
Decreased expression of Gbx2, a gene involved in heart development Gbx2 has been studied extensively as a regulator of midbrain development (Joyner et al., 2000) . However, it is also expressed in the branchial arches and PE (Shamim and Mason, 1998) . We found Gbx2 to have reduced expression in Tbx1 null embryos. Expression analysis shows that expression was almost entirely lost from the PE. This is in contradistinction to the reduced expression of Pax9 described above, and robust expression of Pax1 and Eya1. In addition, an expression zone in the caudal region of the first branchial arch and rostral region of the second arch was reduced or lost. Gbx2 mutants have cardiovascular defects similar to those seen in 22q11DS: an IAA-B, right aortic arch and retroesophageal right subclavian artery (Erik Meyers, personal communication). More rarely, they also have VSDs and outflow tract malformations. Gbx2 is regulated by Fgf-8 in the isthmic organizer (Garda et al., 2001; Ye et al., 2001) , of interest given the interaction of Tbx1 and Fgf-8 controlled pathways (Vitelli et al., 2002b) . The incidence of cardiovascular defects was substantially increased in Gbx2 À/À Fgf +/À compound mutants vs.
Gbx2
À/À alone (Erik Meyers, personal communication). Thus, Gbx2 is an excellent candidate to be a primary or secondary target of Tbx1, and cross-breeding of Tbx1 and Gbx2 mutants should detect any epistatic interaction. Fgf-8 hypomorphic mutants have 22q11DS-like heart defects in engineered mouse embryos (Frank et al., 2002) . In view of this, the down-regulation of Fgf-10 seen in Tbx1 À/À embryos, and the epistatic interaction between Tbx1 and Fgf-8, we interrogated the array data to examine Fgf expression. Neither Fgf-8 nor Fgf-10 was represented on the Codelink array and both were below reliable detection levels on the Affymetrix array.
Bioinformatic analysis of the 5 kb immediately upstream of Gbx2, Pax9, Sox3, and Foxg1, but not Six2, revealed potential TBEs similar to a sequence upstream of Fgf10 and activated by Tbx1. These genes are therefore reasonable candidates to be direct targets of Tbx1. However, this TBE was isolated as a Tbx5 binding sequence (Ng et al., 2002) and true Tbx1 binding sites have yet to be defined. We are currently conducting a binding site selection experiment and testing regulation of the respective promoters in transfection studies.
Retinoic acid metabolism
It is of interest that genes involved in retinoic acid metabolism had altered expression levels in mutants. Most notably, in the Df1/+;Tbx1 +/À embryos, Raldh2 was expressed at 12-fold wild type levels on Codelink arrays and 18-fold wild type levels by RTQPCR. Whole-mount in situ hybridizations indicate that this is because the anterior border of the strong mesodermal Raldh2 expression is apparently shifted anteriorly. While this is secondary to an anatomical disruption and does not represent a real shift in the domain of Raldh2 expression, some cells will be in closer proximity to this source of retinoic acid as a result. The increase in Raldh2 expression in the craniofacial mesenchyme, however, is very unlikely to be secondary to anatomical disruption. This expression zone has not been remarked on previously, presumably because Raldh2 is weakly expressed here in wild type embryos. The retinoic acid catabolizing enzyme Cyp26a1 was expressed at significantly lower levels in both array sets and by RTQPCR. Cyp26a1 reduces RA signaling, acting as a sink. Cyp26a1 À/À embryos have spina bifida, hindgut, urogenital tract, and heart defects (Abu- Sakai et al., 2001) , and the caudal dysgenesis phenotype of Cyp26a1 À/À embryos can be rescued by hemizygosity of Raldh2 (Niederreither et al., 2002 ). Thus, the reduced level of Cyp26a1 expression may result in a local retinoic acid toxicity that exacerbates the Tbx1 null phenotype. The situation with regard to retinoid regulation is complicated by the down-regulation of other retinoic acid synthesizing enzymes Aldh1a1 (0.69 on Affymetrix array) and Aldh1a4 (0.32 on Codelink array, and 0.39 by RTQPCR), and the existence of two other Cyp26 family members (MacLean et al., 2001; Tahayato et al., 2003) . The expression and functional analysis of the Cyp26 family, and the potential role of disturbance of retinoid metabolism in Tbx1 À/À embryos are currently being analyzed further.
Other genes expressed in the branchial arches and differentially regulated in Df1/+;Tbx1 +/À mutants At E8.5, Six2 is expressed in the foregut and a mesodermal cell population at the anterior hindbrain level, this expression become more widespread and including the branchial arches and the ectoderm between the maxillary and mandibular arches at E9.5 (Ohto et al., 1998) . No gene targeting has been reported.
Nkx5.3 (Hmx1) is first expressed at E9.5 in the trigeminal (V) ganglion and 1 day later is seen in the eye, the mesenchyme underlying the hindbrain, the second branchial arch, and dorsal root ganglia (Wang et al., 2000) . The requirement for Nxk5.3 during development is unknown, but it has been shown that Nxk5.3 antagonizes Nkx2.5 activity (Amendt et al., 1999) , Nxk2.5 being required for normal cardiac morphogenesis.
Previous work has shown that the failure of the caudal pharyngeal arches to form results in ectopic neural crest migration. The microarray analysis did not uncover any widespread changes in neural crest-expressed genes. We did confirm down-regulation of endothelin-1 (Et-1) as previously reported in the vgo zebrafish model (Piotrowski et al., 2003) , with a 56% level by RTQPCR. Et-1 controls the expression of Dlx family transcription factors, and Dlx6 was significantly down-regulated in the Codelink arrays, and at 68% wild type levels by RTQPCR. However, no effect of Ece1 (endothelin converting enzyme) mutations on the Tbx1 +/À phenotype was observed in mouse crosses (Morishima et al., 2003) .
In summary, we have shown that twice linear amplified target from dissected pharyngeal regions of single E9.5 embryos can distinguish haploid from diploid gene dosage when the Df1 deletion is present. We detected various changes in gene expression in embryos nullizygous for Tbx1 and validated several by real-time quantitative PCR. Using in situ hybridization, we have confirmed changes in the expression of Pax9, Gcm2, and Gbx2 in mutant embryos. Further work is required to determine whether the diminished expression of these genes is due to the fact that they are downstream of Tbx1 in a developmental pathway, or whether particular subsets of cells expressing these genes are absent or reduced in Tbx1 nulls. This might be achieved through biochemical analysis of target gene promoters, breeding of mice with a view to detecting epistatic interactions, and use of mice with lineage tracers. Either way, the detection of differential expression of these genes with a known role in embryogenesis shows that microarray analysis of mutant embryos is a potentially useful tool for uncovering genes involved in the development of specific structures. Extending the analysis to microarrays containing more genes of unknown function could identify novel genes acting in these pathways.
